Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant HIPEC with raltitrexed + mitomycin after curative colorectal cancer surgery
ChiCTR2600135095Phase 4Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of raltitrexed and mitomycin c in colorectal cancer (CRC) (2 arms), sponsored by Shandong Cancer Hospital. Primary endpoint: 3-year peritoneal metastasis rate. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
raltitrexedmitomycin c
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2600135095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600135095.